Silke Buda
YOU?
Author Swipe
View article: COVID-ARE-Konsultationsinzidenz
COVID-ARE-Konsultationsinzidenz Open
Im Datensatz "COVID-ARE-Konsultationsinzidenz" des Robert Koch-Instituts werden wöchentliche Inzidenzen von ambulanten Konsultationen mit akuter respiratorischer Erkrankung (ARE) und zusätzlicher COVID-19-Diagnose in Deutschland bereitgest…
View article: SARI-Hospitalisierungsinzidenz
SARI-Hospitalisierungsinzidenz Open
Im Datensatz "SARI-Hospitalisierungsinzidenz" des Robert Koch-Instituts werden die wöchentlichen Inzidenzen schwerer akuter respiratorischer Infektionen (SARI) auf Bundesebene in Deutschland bereitgestellt. Die Daten stammen aus der syndro…
View article: ARE-Konsultationsinzidenz
ARE-Konsultationsinzidenz Open
Im Datensatz "ARE-Konsultationsinzidenz" des Robert Koch-Instituts werden wöchentliche Inzidenzen von ambulanten Konsultationen mit akuter respiratorischer Erkrankung (ARE) in Deutschland bereitgestellt. Die Daten stammen vom ARE-Praxis-Se…
View article: GrippeWeb - Daten des Wochenberichts
GrippeWeb - Daten des Wochenberichts Open
Im Datensatz "GrippeWeb - Daten des Wochenberichts" des Robert Koch-Instituts werden wöchentliche, bevölkerungsbasierte Schätzungen zur Inzidenz akuter respiratorischer Erkrankungen (ARE) und grippeähnlicher Erkrankungen (ILI) in Deutschla…
View article: Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case–control studies, 2015/16–2023/24
Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case–control studies, 2015/16–2023/24 Open
View article: Development and implementation of a nowcasting method for the syndromic surveillance of severe acute respiratory infections (SARI) in Germany
Development and implementation of a nowcasting method for the syndromic surveillance of severe acute respiratory infections (SARI) in Germany Open
Background In Germany, diagnosis-based hospital surveillance of severe acute respiratory infections (SARI) incidence is operated weekly. However, diagnosis data from the most recent weeks is provisional and may be subject to systematic cha…
View article: COVID-19 vaccine effectiveness against hospitalisation in older adults, VEBIS hospital network, Europe, September 2024--May 2025
COVID-19 vaccine effectiveness against hospitalisation in older adults, VEBIS hospital network, Europe, September 2024--May 2025 Open
View article: Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24
Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24 Open
Introduction Influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe in 2023/24, with A(H1N1)pdm09 dominance. First influenza infections in childhood may lead to different vaccine effectiveness (VE) in subsequent years.…
View article: Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance
Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance Open
Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co‐circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Ger…
View article: COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network
COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network Open
We estimated the effectiveness of 2024/25 COVID‐19 vaccination against medically attended SARS‐CoV‐2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a…
View article: COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network
COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network Open
View article: Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024 Open
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at prim…
View article: COVID-SARI-Hospitalisierungsinzidenz
COVID-SARI-Hospitalisierungsinzidenz Open
Zur Einschätzung der Krankheitslast schwerer symptomatischer Atemwegsinfektionen im stationären Bereich wird mithilfe von Daten aus der syndromischen Krankenhaussurveillance ICOSARI die Inzidenz der Fälle, die mit einer schweren akuten res…
View article: Participatory, Virologic, and Wastewater Surveillance Data to Assess Underestimation of COVID-19 Incidence, Germany, 2020–2024
Participatory, Virologic, and Wastewater Surveillance Data to Assess Underestimation of COVID-19 Incidence, Germany, 2020–2024 Open
Using participatory, virologic, and wastewater surveillance systems, we estimated when and to what extent reported data of adult COVID-19 cases underestimated COVID-19 incidence in Germany. We also examined how case underestimation evolved…
View article: COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans Open
Importance In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns. Objective To estimate the effectiveness of COVID-…
View article: Authors’ response: Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic
Authors’ response: Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic Open
Preview this article: Authors' response: Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Page 1 of 1 < Previous page | Next page > …
View article: Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022–23 VEBIS multicentre study in Europe
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022–23 VEBIS multicentre study in Europe Open
Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022-23 influenza season was not affected by use o…
View article: COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022 Open
Background Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1…
View article: Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Germany, 2021 to 2023
Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Germany, 2021 to 2023 Open
Background Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. Aim To describe, for children aged < 5 years, the 2021 and 2022/23 RSV seasons in Germany. Me…
View article: Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024 Open
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 count…
View article: The increase in invasive bacterial infections with respiratory transmission in Germany, 2022/2023
The increase in invasive bacterial infections with respiratory transmission in Germany, 2022/2023 Open
The reason for the marked rise in invasive bacterial infections may be an increased circulation of respiratory pathogens and elevated susceptibility in the population after relaxation of the measures taken to prevent COVID-19 infection. Co…
View article: Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network Open
We conducted a multicentre hospital‐based test‐negative case–control study to measure vaccine effectiveness (VE) against PCR‐confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenz…
View article: COVID-ARE-Konsultationsinzidenz
COVID-ARE-Konsultationsinzidenz Open
Zur Einschätzung der Krankheitslast symptomatischer Atemwegsinfektionen im ambulanten Bereich wird die Inzidenz der Arztbesuche wegen einer akuten respiratorischen Erkrankung mit zusätzlicher COVID-19-Diagnose pro 100.000 Einwohner mithilf…
View article: SARI-Hospitalisierungsinzidenz
SARI-Hospitalisierungsinzidenz Open
Zur Einschätzung der Krankheitslast schwerer symptomatischer Atemwegsinfektionen im stationären Bereich wird mithilfe von Daten aus der syndromischen Krankenhaussurveillance ICOSARI die Inzidenz der Fälle, die mit einer schweren akuten res…
View article: COVID-SARI-Hospitalisierungsinzidenz
COVID-SARI-Hospitalisierungsinzidenz Open
Zur Einschätzung der Krankheitslast schwerer symptomatischer Atemwegsinfektionen im stationären Bereich wird mithilfe von Daten aus der syndromischen Krankenhaussurveillance ICOSARI die Inzidenz der Fälle, die mit einer schweren akuten res…
View article: ARE-Konsultationsinzidenz
ARE-Konsultationsinzidenz Open
Zur Einschätzung der Krankheitslast akuter Atemwegsinfektionen im ambulanten Bereich wird die Inzidenz der Arztbesuche wegen einer akuten respiratorischen Erkrankung pro 100.000 Einwohner mit Daten aus einem Netzwerk primärversorgender Pra…
View article: GrippeWeb - Daten des Wochenberichts
GrippeWeb - Daten des Wochenberichts Open
GrippeWeb ist ein Online-Portal des Robert Koch-Instituts (RKI). Es wurde im Jahr 2011 gegründet und ist das erste Webportal, das die Aktivität akuter Atemwegserkrankungen (ARE) in Deutschland beobachtet, und dabei Informationen direkt aus…
View article: COVID-ARE-Konsultationsinzidenz
COVID-ARE-Konsultationsinzidenz Open
Zur Einschätzung der Krankheitslast symptomatischer Atemwegsinfektionen im ambulanten Bereich wird die Inzidenz der Arztbesuche wegen einer akuten respiratorischen Erkrankung mit zusätzlicher COVID-19-Diagnose pro 100.000 Einwohner mithilf…
View article: COVID-SARI-Hospitalisierungsinzidenz
COVID-SARI-Hospitalisierungsinzidenz Open
Zur Einschätzung der Krankheitslast schwerer symptomatischer Atemwegsinfektionen im stationären Bereich wird mithilfe von Daten aus der syndromischen Krankenhaussurveillance ICOSARI die Inzidenz der Fälle, die mit einer schweren akuten res…
View article: SARI-Hospitalisierungsinzidenz
SARI-Hospitalisierungsinzidenz Open
Zur Einschätzung der Krankheitslast schwerer symptomatischer Atemwegsinfektionen im stationären Bereich wird mithilfe von Daten aus der syndromischen Krankenhaussurveillance ICOSARI die Inzidenz der Fälle, die mit einer schweren akuten res…